(RTTNews) - Novavax, Inc. (NVAX), Friday announced that the Novavax COVID-19 Vaccine, Adjuvanted (2024-2025 Formula) has received Emergency Use Authorization from the U.S. Food and Drug Administration ...

GAITHERSBURG, Md., Oct. 3, 2023 /PRNewswire/ -- Novavax, Inc., a global company advancing protein-based vaccines with its novel Matrix-M ™ adjuvant, today announced that the Novavax COVID-19 Vaccine, ...

On August 30, 2024, the Food and Drug Administration amended the emergency use authorization (EUA) of Novavax COVID-19 Vaccine, Adjuvanted to include the updated 2024-2025 formula. The Novavax ...

The FDA granted emergency use authorization (EUA) for an updated Novavax COVID-19 vaccine to protect against hospitalization and death from circulating variants. The protein-based shot represents a ...

Novavax’s alliance with Sanofi came at an opportune time for the beleaguered vaccine developer. Its protein-based Covid-19 vaccine never reached the revenue highs achieved by the messenger RNA ...

Novavax, sold under the brand name Nuvaxovid, is a protein-based COVID-19 vaccine — the same technology used to develop many other common vaccines, including those for influenza and shingles.

GAITHERSBURG, Md., Aug. 30, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced the Novavax COVID-19 ...

Novavax COVID-19 Vaccine, Adjuvanted (2024-2025 Formula) has not been approved or licensed by the FDA but has been authorized for emergency use by the FDA, under an EUA to prevent Coronavirus Disease ...